Gabapentin Capsule
Product Images NDC 83209-663

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 83209-663). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Boswell Pharmacy Services Llc D/b/a Bps Wholesale, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 400mg -30 (Gabapentin 400mg 16714 0663 02 30)

Label for Gabapentin USP 400 mg capsules from Boswell Pharmacy Services LLC d/b/a BPS Wholesale. The package contains 30 capsules with NDC 83209-663-30. Includes storage instructions and batch details, with repackaging information by BPS Wholesale, Jennerstown, PA.*

FDA Label Image

Equation Of Cockcroft And Gault (Gabapentin Fig1)

An equation formula showing the calculation of Creatinine Clearance (CLCr) based on age, weight, serum creatinine, and a correction factor for female patients.*

FDA Label Image

Fig-2 (Gabapentin Fig2)

A line graph showing mean pain scores over eight weeks comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks including a 4-week dose titration period and a 4-week fixed dose period. The y-axis measures mean pain score from 0 to 10, with Gabapentin showing a greater reduction in pain score compared to placebo over time.*

FDA Label Image

Fig-3 (Gabapentin Fig3)

A line graph depicting mean pain scores over seven weeks for three groups: placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents time in weeks, including a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows the mean pain score, decreasing over time, with gabapentin groups showing a greater reduction than placebo.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

Bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing response rates between placebo (PBO) and Gabapentin (GBP) at different dosages in two studies. Study 1 shows 12% for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance indicators (** p<0.01, *** p<0.001) are included above GBP bars.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

A scatter plot illustrating the percentage difference relative to daily dose of Gabapentin (mg) in three studies labeled a, b, and c. The x-axis represents daily doses in milligrams (600 to 1800 mg), and the y-axis shows the percentage difference from 2% to 22%. Different marker styles correspond to the three studies.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure diagram of gabapentin, showing its cyclohexane ring with attached amino and carboxyl functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.